Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixekizumab vs methotrexate in psoriatic arthritis dactylitis
2022-503119-40-00Phase 3Authorised
- Sponsor
- Azienda Ospedaliera Ordine Mauriziano di Torino
- Start
- Apr 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of ixekizumab in psoriatic arthritis (PsA) (2 arms), sponsored by Azienda Ospedaliera Ordine Mauriziano di Torino. Primary endpoints: Efficacy of ixekizumab vs methotrexate in psoriatic arthritis dactylitis and Change in DACTOS score and ultrasound dactylitis lesions. Planned start Apr 2025; status: authorised.
02
Drugs
ixekizumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on 2022-503119-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503119-40-00.